



CETEC localement avancé



REACH

REACH




REACH

Unfit Cohort: **Primary endpoint**

Kaplan Meier estimate of progression free survival (PFS)

Median follow-up = 21.3 months (IQR 14.5-28.3) (similar in both arms)



Abstract 110

© 2021 by American Society of Clinical Oncology. All rights reserved. Reproduction of this abstract is permitted for personal use only. For all other uses, permission must be obtained from the American Society of Clinical Oncology.

PFS at 2 years

44% (p < 0.001) in Avelumab + Cetuximab

vs


21% (p < 0.001) in Cetuximab

Adjusted HR 0.84 for PFS
(95% CI 0.62-1.15)

one-sided p-value = 0.14

REACH

Key secondary endpoint
Cumulative incidence of distant metastasis progression



Cumulative Incidence of metastases

14.3% (95%CI 8%-20%)

in **Cetuximab**

Vs

5.4% (95%CI 1.5%-8%)

in **Avelumab-Cetuximab**

Adjusted* HR 0.31 (95%CI 0.13-0.72)


p=0.007

REACH : fit




JAVELIN 100

JAVELIN 100




JAVELIN 100

PFS




JAVELIN 100 : OS



KEYNOTE 412

KEYNOTE 412



Conclusion

- ▶ Absence de bénéfice démontré en association avec radiothérapie en situation localement avancé
- ▶ Différents essais randomisés en cours
- ▶ Sélection des patients : statut PDL1 ?
- ▶ Effet de l'irradiation cervicale ?
- ▶ Quelle séquence ? Concomitant ? Adjuvant ?

53^E CONGRÈS SFCCF 2021

CONGRÈS DE LA SOCIÉTÉ FRANÇAISE DE CARCINOLOGIE CERVICO-FACIALE



CONTACT :



Dfarneti@chu-grenoble.fr

